PFKM and cancer: Rather than reducing PFKB3 activities, which leads to a reduction in F2,6BP levels, partial inhibition of PFK1 activities by small molecule inhibitors appears to be the more straightforward mechanism to control dysregulated glycolytic flux in cancer cells.